Print Friendly, PDF & Email

NCT/Study#

NCT04241185 /

MK-3475-992-005

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Study The Efficacy And Safety Of Pembrolizumab (MK-3475) In Combination With Chemoradiotherapy (CRT) Versus CRT Alone In Participants With Muscle-Invasive Bladder Cancer (MIBC) (KEYNOTE-992)

DISEASE GROUP:
Genito-Urinary
current phase:
Phase III
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: